For many attendees, this year’s J.P. Morgan Healthcare Conference didn’t seem to live up to its trademark frenetic energy. Last year, Bristol-Myers' $74 billion Celgene deal announcement—which happened just days before JPM—set the biopharma world abuzz, and Lilly kept the ball rolling with its $8 billion Loxo pact on Day 1 of the meeting. But this year? Crickets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,